ContraFect to Present at Cantor Antibiotics Summit
11 janv. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at 10th Annual Biotech Showcase
03 janv. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
15 nov. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
10 nov. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Third Quarter 2017 Financial Results
09 nov. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Melinta Therapeutics Announces Successful Completion of Merger
06 nov. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
30 oct. 2017 08h01 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
ContraFect to Present New Data on CF-301 at ID Week 2017
29 sept. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at The MicroCap Conference
28 sept. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens
18 sept. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...